VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

FRA:VX1 • US92532F1003

404.85 EUR
+5.3 (+1.33%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to VX1. VX1 was compared to 78 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making VX1 a very profitable company, without any liquidiy or solvency issues. VX1 has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • VX1 had positive earnings in the past year.
  • VX1 had a positive operating cash flow in the past year.
  • Of the past 5 years VX1 4 years were profitable.
  • The reported operating cash flow has been mixed in the past 5 years: VX1 reported negative operating cash flow in multiple years.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • With an excellent Return On Assets value of 14.78%, VX1 belongs to the best of the industry, outperforming 89.74% of the companies in the same industry.
  • With an excellent Return On Equity value of 21.22%, VX1 belongs to the best of the industry, outperforming 93.59% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 93.59% of the companies in the same industry.
  • VX1 had an Average Return On Invested Capital over the past 3 years of 17.53%. This is significantly above the industry average of 11.39%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 15.67%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.35%, VX1 belongs to the top of the industry, outperforming 87.18% of the companies in the same industry.
  • VX1 has a better Operating Margin (38.70%) than 94.87% of its industry peers.
  • VX1's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 86.28%, VX1 is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VX1 is creating value.
  • The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, VX1 has less shares outstanding
  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.8
WACC8.72%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • VX1 has a Current ratio (2.36) which is comparable to the rest of the industry.
  • VX1 has a Quick Ratio of 2.00. This is a normal value and indicates that VX1 is financially healthy and should not expect problems in meeting its short term obligations.
  • VX1 has a Quick ratio of 2.00. This is comparable to the rest of the industry: VX1 outperforms 46.15% of its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • Measured over the past years, VX1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.27% on average per year.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.55%

3.2 Future

  • VX1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.80% yearly.
  • Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 9.15% on average per year.
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue Next Year8.7%
Revenue Next 2Y9.21%
Revenue Next 3Y9.38%
Revenue Next 5Y9.15%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 25.85 indicates a quite expensive valuation of VX1.
  • Based on the Price/Earnings ratio, VX1 is valued cheaper than 83.33% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.99. VX1 is around the same levels.
  • VX1 is valuated rather expensively with a Price/Forward Earnings ratio of 23.34.
  • Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, VX1 is valued at the same level.
Industry RankSector Rank
PE 25.85
Fwd PE 23.34
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 80.77% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, VX1 is valued cheaper than 84.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.18
EV/EBITDA 23.82
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VX1 does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of VX1 may justify a higher PE ratio.
PEG (NY)2.41
PEG (5Y)2.11
EPS Next 2Y11.49%
EPS Next 3Y10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VX1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERTEX PHARMACEUTICALS INC

FRA:VX1 (2/20/2026, 7:00:00 PM)

404.85

+5.3 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap102.72B
Revenue(TTM)N/A
Net Income(TTM)3.68B
Analysts80
Price Target449.01 (10.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)5.57%
PT rev (3m)6.09%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)0.16%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 25.85
Fwd PE 23.34
P/S 10.3
P/FCF 36.18
P/OCF 32.47
P/B 6.97
P/tB 7.64
EV/EBITDA 23.82
EPS(TTM)15.66
EY3.87%
EPS(NY)17.35
Fwd EY4.28%
FCF(TTM)11.19
FCFY2.76%
OCF(TTM)12.47
OCFY3.08%
SpS39.31
BVpS58.08
TBVpS52.99
PEG (NY)2.41
PEG (5Y)2.11
Graham Number143.05
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 15.67%
ROICexc 22.65%
ROICexgc 25.38%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC8.72%
ROIC/WACC1.8
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.55%
Revenue Next Year8.7%
Revenue Next 2Y9.21%
Revenue Next 3Y9.38%
Revenue Next 5Y9.15%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year824.9%
EBIT Next 3Y127.59%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 6 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 10.74% in the next year.